Bind raises $12.4 million

Bind Biosciences Inc. (Cambridge, Mass.) raised $12.4 million in a series C-1 round led by new investor Endeavour Vision. All existing investors, including Polaris Venture Partners; Flagship Ventures; Arch Venture Partners; NanoDimension; and DHK Investment, as well as private investors participated. Bind's lead candidate, BIND-014, is expected to begin Phase I testing this year to treat solid tumors. BIND-014 is a nanoparticle containing docetaxel that concentrates in the neovasculature surrounding tumors and targets prostate-specific membrane antigen ( PSMA). Taxotere docetaxel is marketed by sanofi-aventis Group (Euronext:SAN; NYSE:SNY). ...